EP Patent

EP3831380A2 — Psma binding ligand-linker conjugates and methods for using

Assigned to Purdue Research Foundation · Expires 2021-06-09 · 5y expired

What this patent protects

Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. …

USPTO Abstract

Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

Drugs covered by this patent

Patent Metadata

Patent number
EP3831380A2
Jurisdiction
EP
Classification
—
Expires
2021-06-09
Drug substance claim
No
Drug product claim
No
Assignee
Purdue Research Foundation
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.